Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer

BACKGROUND: Despite improvement of tumour response rates in patients with progressive and metastatic cancer, immune checkpoint inhibitors (ICM) induce toxicities in cancer patients. Viscum album L. (VA, mistletoe) extracts are applied as add-on cancer therapy especially in German speaking countries...

Descripción completa

Detalles Bibliográficos
Autores principales: Thronicke, Anja, Steele, Megan L., Grah, Christian, Matthes, Burkhard, Schad, Friedemann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729272/
https://www.ncbi.nlm.nih.gov/pubmed/29237435
http://dx.doi.org/10.1186/s12906-017-2045-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729272/
https://www.ncbi.nlm.nih.gov/pubmed/29237435
http://dx.doi.org/10.1186/s12906-017-2045-0

Ejemplares similares